US-based biotech startup Soin Neuroscience has tested its spinal cord stimulation system on humans, leveraging very low-frequency stimulation.
The company has commenced the initial testing of its TunedTX platform on humans to assess its safety and tolerance through low-frequency stimulation.
Go deeper with GlobalData
This spinal cord stimulation system has not yet received approval from the US Food and Drug Administration and is intended for investigational use only.
Soin Neuroscience founder Dr Amol Soin said: “The very low-frequency stimulation platform is one of many novel waveforms across both high and low frequencies that we are testing to help create a versatile experience for our patients while arming our clinicians with the tools they need to help patients achieve maximal pain relief.
“Honestly, right now, we are just testing things in the lab to see what works, what doesn’t work and what is practical to use. Sometimes these experiments blossom into viable programmes and sometimes they are a dead end.”
In January 2020, the company announced that it developed a spinal cord stimulation device for the treatment of chronic pain.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSpinal cord stimulation involves the insertion of electrical leads into the epidural space of the spine, where they deliver electrical stimulation to alleviate a patient’s pain perception.
The company is also developing machine learning and artificial intelligence-based technologies to help physicians’ decision-making on precision medicine.
